Welcome to our dedicated page for Boundless Bio news (Ticker: BOLD), a resource for investors and traders seeking the latest updates and insights on Boundless Bio stock.
Boundless Bio, Inc. (symbol: BOLD) is a clinical-stage oncology company leading a transformative approach in cancer therapeutics. The company's primary focus is on addressing oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), which is a key driver in over 14% of cancer cases. This novel focus on ecDNA allows Boundless Bio to develop innovative treatments for a significant unmet medical need.
The company's flagship product, BBI-355, is an oral and selective inhibitor of checkpoint kinase 1 (CHK1). This compound is designed to disrupt the replication and transcription of ecDNA in cancer cells, offering a targeted approach to treatment. BBI-355 is currently undergoing clinical trials, showing promise in its ability to manage oncogene amplification more effectively than existing therapies.
Beyond its core product, Boundless Bio is actively engaged in multiple research and development projects to further expand its pipeline. The company collaborates with leading academic and industry partners to enhance the understanding and treatment of ecDNA in oncology. These partnerships are crucial for driving innovation and ensuring that new therapies reach the patients who need them most.
Financially, Boundless Bio is well-positioned to advance its clinical programs, supported by robust funding from investors who recognize the potential of their groundbreaking work. With a clear focus on improving patient outcomes, Boundless Bio continues to make strides in the oncology field, aiming to offer new hope to cancer patients worldwide.
For the latest updates on Boundless Bio's financial performance, clinical trial developments, and industry collaborations, stay tuned to the latest news from the company.
Boundless Bio (BOLD) announced significant updates to its pipeline and leadership team. The company has decided not to advance BBI-825 into Part 2 of the STARMAP trial due to pharmacokinetic data concerns and increasing development costs. However, enrollment continues for BBI-355's Phase 1/2 POTENTIATE trial, with initial clinical data expected in H2 2025.
The company's third ecDTx program is progressing, targeting a novel kinesin for ecDNA segregation, with development candidate nomination expected by mid-2025 and IND submission planned for H1 2026. Leadership changes include the departure of CMO Klaus Wagner and CBO Neil Abdollahian, with James L. Freddo appointed as Interim CMO. The company's operating runway has been extended into 2027.
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology and oncogene amplified cancers, has announced its participation in Piper Sandler's 36th Annual Healthcare Conference.
President and CEO Zachary Hornby will participate in a fireside chat on Wednesday, December 4, 2024, at 3:30 p.m. ET in New York. The session will be available via live and archived webcast through the company's website under the Investors section.
Boundless Bio (BOLD) reported Q3 2024 financial results, highlighting progress in its clinical trials. The company maintains a strong cash position of $167.1 million, providing runway into Q4 2026. Key developments include ongoing enrollment in BBI-355 POTENTIATE and BBI-825 STARMAP trials, with initial proof-of-concept data expected in H2 2025. Q3 financials show R&D expenses of $14.1M (up from $11.6M in Q3 2023), G&A expenses of $4.6M (up from $3.3M), and a net loss of $16.5M (increased from $13.2M).
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology for treating oncogene amplified cancers, announced its participation in the 2024 Guggenheim Global Healthcare Conference. President and CEO Zachary Hornby will participate in a fireside chat on Tuesday, November 12, 2024, at 2:30 p.m. ET in Boston, MA. The session will be available via live and archived webcast in the Investors section of the company's website under 'Events & Presentations'.
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology for treating oncogene amplified cancers, announced the departure of CFO Jami Rubin for personal reasons. The company does not plan to hire a successor CFO immediately. David Hinkle, Senior VP of Finance and Controller, will assume responsibility for Finance operations and the roles of principal financial and accounting officer.
CEO Zachary Hornby expressed gratitude for Rubin's contributions, particularly in the company's successful IPO and corporate strategy refinement. Rubin stated her pride in Boundless Bio's accomplishments and confidence in the company's future success, citing ongoing clinical trials for lead programs and a strong balance sheet to support their advancement.
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focusing on extrachromosomal DNA (ecDNA) biology, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's executives, Zachary Hornby (President and CEO) and Jami Rubin (CFO), will engage in a fireside chat session on Wednesday, September 18, 2024, at 10:20 a.m. ET in New York, NY.
Boundless Bio aims to develop transformative therapies for patients with previously intractable oncogene amplified cancers. Interested parties can access a live and archived webcast of the session through the 'Events & Presentations' section of the company's website under the Investors tab.
Boundless Bio (Nasdaq: BOLD) provided business updates and Q2 2024 financial results. Key points include:
1. BBI-355 POTENTIATE trial ongoing; initial proof-of-concept data now expected in H2 2025.
2. BBI-825 STARMAP trial ongoing; initial data expected in H2 2025.
3. ECHO ecDNA diagnostic validated for use in BBI-355 trial.
4. Operations streamlined to extend runway into Q4 2026.
5. Q2 2024 financials: Cash position $179.3M, R&D expenses $14.7M, G&A expenses $4.7M, Net loss $17.0M.
The company is focusing on core ecDTx programs while scaling back early discovery efforts. Enrollment in BBI-355 combination cohorts is slower than projected, prompting initiatives to accelerate recruitment.
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference. President and CEO Zachary Hornby, along with CFO Jami Rubin, will represent the company in a fireside chat on June 12 at 3:20 p.m. ET in Miami, FL. The session will be available via live and archived webcast on the company’s website under the 'Events & Presentations' section.
Boundless Bio (Nasdaq: BOLD) reported their first quarter 2024 financial results, highlighting progress on their clinical trials. The company's Phase 1/2 POTENTIATE trial for BBI-355, a novel CHK1 inhibitor, and the Phase 1/2 STARMAP trial for BBI-825, a selective RNR inhibitor, have shown promising advancements. With a pro forma cash position of approximately $200 million following a $100 million IPO, Boundless Bio is well-positioned for future growth and development.
Boundless Bio (Nasdaq: BOLD) will be presenting at the Citizens JMP Life Sciences Conference 2024. The company's CFO will present on ecDNA biology therapies for oncogene amplified cancers. The webcast will be available on the company's website.
FAQ
What is the current stock price of Boundless Bio (BOLD)?
What is the market cap of Boundless Bio (BOLD)?
What is Boundless Bio, Inc.?
What is ecDNA and why is it important?
What is BBI-355?
What are the current projects at Boundless Bio?
Who are Boundless Bio's partners?
Is Boundless Bio financially stable?
How does BBI-355 work?
What phase are the clinical trials for BBI-355?
How can I stay updated on Boundless Bio's latest news?
What is the significance of targeting oncogene-amplified tumors?
